Opinion statement
Nonalcoholic steatohepatitis (NASH) is an important medical condition and there is great public health concern related to its increasing incidence and potential implications for the development of end-stage liver disease. NASH represents a progression beyond simple lipid deposition in the liver parenchyma, requiring histologic evidence for hepatocyte injury such as ballooning degeneration, Mallory bodies, and/or pericellular fibrosis that can potentially lead to progressive liver injury and eventually cirrhosis. It is believed that several insults contribute to the evolution of hepatic injury such as insulin dysregulation, lipid deposition, oxidative free radicals, and lipid perioxidation. Initial treatment protocols for NASH focus on various aspects of injury in an attempt to control insulin imbalances, improve lipid regulation, reduce free radicals, and ameliorate the inflammatory process. No therapy is conclusively beneficial in all individuals, but preliminary data suggest several approaches that hold promise.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Younossi ZM: Nonalcoholic fatty liver disease. Curr Gastroenterol Rep 1999, 1: 57–62.
Falck-Ytter Y, Younossi ZM, Marchesini G, et al.: Clinical features and natural history of nonalcoholic steatosis syndromes. Sem Liver Dis 2001, 21: 17–26. An excellent and informative review of NASH.
Bacon BR, Farahvash MJ, Janney CG, et al.: Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107: 1103–1109.
Matteoni CA, Younossi ZM, Gramlich T, et al.: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116: 1413–1419.
Teli MR, James OF, Burt AD, et al.: The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22: 1714–1719.
Ixon JB, Bhathal PS, O’Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121: 91–100. Examines the epidemiologic association of obesity (metabolic syndrome) and NAFL.
Angulo P, Keach JC, Batts KP, et al.: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999, 30: 1356–1362.
Gramlich T, Kleiner D, McCullough A, et al.: Pathologic Features Associated with Fibrosis in Non-Alcoholic Fatty Liver Disease. Hum Pathol 2004, 35: 196–199.
Ratziu V, Giral P, Charlotte F, et al.: Liver fibrosis in overweight patients. Gastroenterology 2000, 118: 1117–23.
Younossi ZM, Gramlich T, Bacon BR, et al.: Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999, 30: 847–850.
Ong JP, Younossi ZM, Speer C, et al.: Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001, 21: 266–271. Evaluated the significant prognostic impact of NAFL in patients with hepatitis C.
Clark JM, Brancati FL, Diehl AM: Nonalcoholic fatty liver disease. Gastroenterology 2002, 122: 1649–1657.
Wanless IR, Lentz JS: Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 1990, 12: 1106–1110.
Weltman MD, Farrell GC, Hall P, et al.: Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 1998, 27: 128–133.
Younossi ZM, Gramlich T, Matteoni CA, et al.: Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004, 2: 262–265. Defines the epidemiologic association between diabetes and NAFL.
Caldwell SH, Oelsner DH, Iezzoni JC, et al.: Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29: 664–669.
Ong J, Younossi ZM, Reddy V, et al.: Cryptogenic cirrhosis and posttransplant nonalcoholic fatty liver disease. Liver Transpl 2001, 7: 797–801.
Saadeh S, Younossi ZM, Remer EM, et al.: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123: 745–750.
Siegelman ES, Rosen MA: Imaging of hepatic steatosis. Semin Liver Dis 2001, 21: 71–80. Important considerations in radiologic tests to use and their performance in NAFL.
Younossi AM, Gramlich T, Liu YC: Nonalcoholic fatty liver disease: assessments of variability in pathologic interpretations. Mod Pathol 1998, 11: 560–565.
Brunt EM, Janney CG, Di Bisceglie AM, et al.: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999, 94: 2467–2474.
Diehl AM, Goodman Z, Ishak KG: Alcohol-like liver disease in non-alcoholics. A clinical and histological comparison with alcohol-induced liver injury. Gastroenterology 1988, 95: 1056–1062.
Becker U, Gronbaek M, Johansen D, et al.: Lower risk for alcohol-induced cirrhosis in wine drinkers. Hepatology 2002, 35: 868–875.
Day CP, James OFW: Steatohepatitis: a tale of two “hits”? Gastroenterology 1998, 114: 842–845.
Paradis V, Perlemuter G, Bonvoust F, et al.: High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001, 34: 738–744.
Chitturi S, Farrell GC: Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001, 21: 27–41.5.
Leclercq IA, Farrell GC, Field J, et al.: CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 2000, 105: 1067–1075.
Pessayre D, Mansouri A, Haouzi D, et al.: Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999,15: 367–373.
Rao MS, Reddy JK: Peroxisomal beta-oxidation and steatohepatitis. Semin Liver Dis 2001, 21: 43–55.
Whelan G, Wood B: The metabolic consequences of jejunoileal bypass for obesity. Aust N Z J Surg 1980, 50: 520–524.
Giannini E, Barreca T, Testa R: Leptin in nonalcoholic steatohepatitis: is it one of the “hits”? Am J Gastroenterol 2001, 96: 2519–2520.
Kaplan LM: Leptin, obesity, and liver disease. Gastroenterology 1998,115: 997–1001.
Uygun A, Kadayifci A, Yesilova Z, et al.: Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000, 95: 3584–9.
Palmer M, Schaffner F: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990, 99: 1408–1413.
Anderson T, Gluud C, Franzmann MB, et al.: Hepatic effects of dietary weight loss in morbidly obese patients. Gastroenterology 1991, 12: 224–229.
Ueno T, Sugawara H, Sujaku K, et al.: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997, 27: 103–107.
Wang RT, Koretz RL, Yee HF: Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med 2003, 115: 554–559. Important study showing the impact of weight loss on liver histology in obese individuals.
Rozental P, Biava C, Spencer H, et al.: Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967, 12: 198–208.
Drenick EJ, Fisler J, Johnson D: Hepatic steatosis after intestinal bypass. Prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982, 82: 535–548.
Harrison SA, Torgerson S, Hayashi P, et al.: Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003, 98: 2485–2490.
Basaranoglu M, Acbay O, Sonsuz A: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999, 31: 384.
Miglio F, Rovati LC, Santoro A, et al.: Efficacy and safety of oral betaine glucuronate in non-alcoholic steatohepatitis. A double-blind, randomized, parallelgroup, placebo-controlled prospective clinical study. Arzneimittelforschung 2000, 50: 722–727.
Lindor KD, Kowdley KV, Heathcote EJ, et al.: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004, 39: 770–778. Randomized trial for therapy of fatty liver disease.
Merat S, Malekzadeh R, Sohrabi MR, et al.: Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003, 38: 414–418. Randomized trial for therapy of fatty liver disease.
Katoh S, Hata S, Matsushima M, et al.: Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy--a randomized controlled trial. Metabolism 2001, 50: 414–417.
Eriksson S, Eriksson KF, Bondesson L: Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986, 220: 83–88.
Campbell JM, Hunt TK, Karam JH, et al.: Jejunoileal bypass as a treatment of morbid obesity. Arch Intern Med 1977, 137: 602–610.
Rogus J, Blumenthal SA: Variations in dietary intake after bypass surgery for obesity. Possible relation to development of fatty liver after jejunoileal bypass. J Am Diet Assoc 1981, 79: 437–440.
Kral JG, Thung SN, Biron S, et al.: Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004, 135: 48–58.
DixonJB,PrithiSB,HughesNR,O’BrienPE: Non-alcoholic fatty liver disease: Improvement in liver histological analysis with weight loss.Hepatology 2004, 39: 1647–1654.
Caldwell SH, Hespenheide EE, Redick JA, et al.: A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96: 519–25.
Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al.: Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003, 38: 1008–1017.
Itoh S, Kanazuka A, Akimoto T: Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis. Dig Dis Sci 2003, 48: 2182–2186.
Promrat K, Lutchman G, Uwaifo GI, et al.: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004, 39: 188–196.
Shadid S, Jensen MD: Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity. Clin Gastroenterol Hepatol 2003, 1: 384–387. One of the first descriptions of a potentially effective therapy.
Marchesini G, Brizi M, Bianchi G, et al.: Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358: 893–894.
Laurin J, Lindor KD, Crippin JS, et al.: Ursodeoxycholic acid or clofibrate in the treatment of nonalcoholinduced steatohepatitis: a pilot study. Hepatology 1996, 23: 1464–1467.
Sabuncu T, Nazligul Y, Karaoglanoglu M, et al.: The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003, 12: 189–192.
Harrison SA, Ramrakhiani S, Brunt EM, et al.: Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003, 98: 926–930.
Abdelmalek MF, Angulo P, Jorgensen RA, et al.: Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001, 96: 2711–2717.
Lavine JE: Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr. 2000, 136: 734–738.
Gulbahar O, Karasu ZA, Ersoz G, et al.: Treatment of nonalcoholic steatohepatitis with N-acetylcysteine. [abstract]. Gastroenterology 2000, 118: A1444.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mulhall, B.P., Younossi, Z.M. Nonalcoholic steatohepatitis. Curr Treat Options Gastro 7, 423–430 (2004). https://doi.org/10.1007/s11938-004-0001-9
Issue Date:
DOI: https://doi.org/10.1007/s11938-004-0001-9